Skip to main content

Table 2 relationship between expression of mir-1307-5p and clinicopathological factors

From: MiR-1307-5p targeting TRAF3 upregulates the MAPK/NF-κB pathway and promotes lung adenocarcinoma proliferation

Pathological parameters

n

Expression level of mir-1307-5p

high expression

Low expression

P

Age

 <55

28

18 (30.5%)

10 (32.3%)

 
    

0.524

 ≥ 55

62

41 (69.5%)

21 (67.7%)

 

Gender

    

 Male

46

34 (57.6%)

12 (38.7%)

 
    

0.069

 Female

44

25 (42.4%)

19 (61.3%)

 

Pathological stage

 I

15

10 (16.9%)

5 (16.1%)

 

 II

55

36 (61.0%)

19 (61.3%)

0.994

 III

20

13 (22.0%)

7 (22.6%)

 

TNM staging

 T

    

 T1

65

47 (79.7%)

18 (58.1%)

 

 T2

21

11 (18.6%)

10 (32.3%)

 
    

0.027

 T3

3

0 (0.0%)

3 (9.7%)

 

 T4

1

1 (1.7%)

0 (0.0%)

 

 N

    

 N0

56

36 (61.0%)

20 (64.5%)

 

 N1

21

15 (25.4%)

6 (19.4%)

 
    

0.797

 N2

13

8 (13.6%)

5 (16.1%)

 

 N3

0

0 (0.0%)

0 (0.0%)

 

 M

    

 M0

90

43 (72.9%)

22 (71.0%)

 
    

0.517

 M1

2

16 (27.1%)

9 (29.0%)

 

Clinical stages

    

 I

40

25 (42.4%)

15 (48.4%)

 

 II

19

15 (25.4%)

4 (12.9%)

 
    

0.504

 III

6

3 (5.1%)

3 (9.7%)

 

 IV

25

16 (27.1%)

9 (29.0%)